There is strong interest across many stakeholders to increase progress around developing treatments for dry age-related macular degeneration (AMD). Advancements in drug discovery and development in dry AMD have been limited and slow due to issues surrounding disease characterization, surrogate endpoints, and clinical trial design. Given the pressing need for progress in the field, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on November 15, 2014, bringing together key stakeholders, to discuss opportunities for advancing drug development for dry AMD, specifically geographic atrophy.